#1 Clinical Trials Search in Europe

Tislelizumab

Tislelizumab is an innovative immunotherapy drug currently being studied in various clinical trials for different types of cancer. This article explores the ongoing research into Tislelizumab’s potential as a treatment option for conditions like liver cancer, lymphoma, lung cancer, and more. We’ll look at how it’s being tested alone and in combination with other therapies to potentially improve outcomes for cancer patients.

Table of Contents

What is Tislelizumab?

Tislelizumab is a type of cancer treatment known as immunotherapy. It is a humanized antibody that targets a protein called PD-1 (programmed cell death protein 1) on immune cells[1]. Tislelizumab is also known by its research name BGB-A317[2].

This drug is designed to help the body’s immune system fight cancer more effectively. It has shown promising results in treating various types of cancer and is being studied extensively in clinical trials[1][2].

How Does Tislelizumab Work?

Tislelizumab works by blocking the PD-1 protein on immune cells. PD-1 normally acts as a “brake” on the immune system, preventing it from attacking healthy cells. However, some cancer cells can exploit this mechanism to evade the immune system[1].

By blocking PD-1, Tislelizumab “releases the brakes” on the immune system, allowing it to recognize and attack cancer cells more effectively. This drug has been engineered to have a high affinity (strong binding) to PD-1 and to minimize binding to other proteins that could reduce its effectiveness[3].

Cancers Treated with Tislelizumab

Tislelizumab is being studied for the treatment of various types of cancer, including:

  • Non-Small Cell Lung Cancer (NSCLC): It is being tested in patients with locally advanced or metastatic NSCLC[2][4].
  • Hepatocellular Carcinoma (Liver Cancer): Studies are ongoing for patients with resectable liver cancer[5].
  • Hodgkin Lymphoma: It’s being investigated for patients who are not suitable for standard chemotherapy[6].
  • Nasopharyngeal Carcinoma: Trials are underway for patients with advanced nasopharyngeal cancer[3].
  • Esophageal Squamous Cell Carcinoma: It’s being tested as a treatment before surgery for this type of esophageal cancer[7].
  • Colon Cancer: Studies are ongoing for patients with early-stage colon cancer with specific genetic characteristics[8].

Clinical Trials and Research

Tislelizumab is currently being studied in numerous clinical trials to determine its effectiveness and safety for various cancer types and stages. These trials are exploring its use as:

  • Neoadjuvant therapy: Treatment given before the main treatment, usually surgery. For example, it’s being tested in patients with resectable liver cancer and esophageal cancer[5][7].
  • Adjuvant therapy: Treatment given after the main treatment to lower the risk of cancer coming back. It’s being studied in patients with early-stage colon cancer[8].
  • Combination therapy: Tislelizumab is being tested in combination with other treatments like chemotherapy and radiation therapy[2][3].
  • Monotherapy: As a standalone treatment, particularly for patients who can’t tolerate or have failed standard treatments[6].

Administration and Dosage

Tislelizumab is typically administered intravenously (through a vein) in a hospital or clinic setting. The most common dosage used in clinical trials is 200 mg every 3 weeks[2][8]. However, the exact dosage and schedule may vary depending on the specific cancer type and treatment plan.

The duration of treatment can range from a few months to up to two years, depending on the study protocol and how well the patient responds to the treatment[8].

Potential Side Effects

As with all medications, Tislelizumab can cause side effects. These are carefully monitored in clinical trials. Common side effects of immunotherapy drugs like Tislelizumab may include:

  • Fatigue
  • Skin rashes
  • Diarrhea
  • Nausea
  • Decreased appetite

More serious side effects can occur, though they are less common. These may include immune-related adverse events, where the immune system attacks healthy organs. Patients in clinical trials are closely monitored for any side effects[8].

Future Prospects

Tislelizumab shows promise in treating various types of cancer, particularly in cases where standard treatments have failed or are not suitable. Ongoing research aims to determine its effectiveness, optimal dosing, and potential combinations with other treatments.

As more clinical trials are completed, we will gain a better understanding of how Tislelizumab can be used to improve cancer treatment outcomes. Patients interested in this treatment should discuss with their oncologist whether participating in a clinical trial might be appropriate for their specific situation.

Cancer Type Trial Phase Treatment Approach Key Outcomes Measured
Hepatocellular Carcinoma Phase II Neoadjuvant Tislelizumab alone or with Lenvatinib Tumor necrosis rate, Disease-free survival
Hodgkin Lymphoma Phase II Tislelizumab monotherapy for patients unsuitable for chemotherapy Overall response rate, Duration of response
Non-small Cell Lung Cancer Phase II Tislelizumab consolidation after radiotherapy or chemoradiation Progression-free survival, Overall survival
Nasopharyngeal Carcinoma Phase II Neoadjuvant and adjuvant Tislelizumab with chemotherapy and radiotherapy Recurrence-free survival, Pathological complete response
Esophageal Squamous Cell Carcinoma Phase II Neoadjuvant Tislelizumab monotherapy Pathological complete response, Objective response rate

FAQ

  • What is Tislelizumab? Tislelizumab is a type of immunotherapy drug called a PD-1 inhibitor. It works by helping the immune system recognize and attack cancer cells more effectively.
  • What types of cancer is Tislelizumab being studied for? Clinical trials are exploring Tislelizumab for several cancer types, including liver cancer (hepatocellular carcinoma), lymphoma, non-small cell lung cancer, nasopharyngeal carcinoma, and esophageal cancer.
  • How is Tislelizumab given to patients in clinical trials? In most trials, Tislelizumab is given as an intravenous (IV) infusion, typically at a dose of 200mg every 3 weeks. The exact schedule can vary depending on the specific trial design.
  • Is Tislelizumab being tested alone or with other treatments? Tislelizumab is being studied both as a single agent and in combination with other treatments. Some trials are testing it with chemotherapy, radiation therapy, or other targeted drugs to see if combining treatments improves outcomes.
  • What are researchers hoping to learn from these clinical trials? Researchers are evaluating Tislelizumab's safety and effectiveness in treating various cancers. They're looking at measures like tumor response rates, survival times, and side effects to determine if it offers benefits over current standard treatments.

Ongoing Clinical Trials on Tislelizumab

  • Study comparing treatment with or without tislelizumab for patients with locally advanced rectal cancer to see if surgery can be avoided

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • A study comparing injection under the skin versus infusion into the vein of tislelizumab with chemotherapy for patients with advanced gastric or gastroesophageal junction cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia France Italy Poland Spain

  • A study of futibatinib combined with tislelizumab, fluorouracil, calcium folinate, and oxaliplatin as first-line treatment for patients with colorectal cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • A study of Pseudovax, molgramostim and tislelizumab combination therapy for patients with pseudomyxoma peritonei cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on the Safety and Effectiveness of OMTX705 with Regorafenib and Tislelizumab for Patients with Advanced Colorectal Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study on Fruquintinib and Tislelizumab for Patients with Metastatic Colorectal Cancer Without Liver Metastases

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Germany

  • Study on Tislelizumab for Elderly Patients with Advanced Esophageal Squamous Cell Carcinoma Unfit for Chemotherapy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Tislelizumab and Chemotherapy for Patients with Stage III PD-L1 Positive Non-Small Cell Lung Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on Dabrafenib, Trametinib, and Imatinib for Patients with Rare and Hard-to-Treat Cancers

    Recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Study of Tislelizumab immunotherapy in patients with liver cancer (hepatocellular carcinoma) who have moderately impaired liver function (Child-Pugh B)

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • PD-1 inhibitor: A type of drug that blocks a protein called PD-1 on immune cells, helping the immune system recognize and attack cancer cells more effectively.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer.
  • Neoadjuvant therapy: Treatment given before the main treatment, often to shrink a tumor before surgery.
  • Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk of the cancer coming back.
  • Hepatocellular carcinoma: The most common type of primary liver cancer.
  • Lymphoma: A type of cancer that begins in cells of the lymph system.
  • Non-small cell lung cancer (NSCLC): A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope.
  • Nasopharyngeal carcinoma: Cancer that forms in tissues of the nasopharynx, the upper part of the throat behind the nose.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival: The length of time from the start of treatment for a disease that patients are still alive.

References

  1. https://clinicaltrials.gov/study/NCT05058560
  2. https://clinicaltrials.gov/study/NCT03745222
  3. https://clinicaltrials.gov/study/NCT05448885
  4. https://clinicaltrials.gov/study/NCT05758116
  5. https://clinicaltrials.gov/study/NCT05807776
  6. https://clinicaltrials.gov/study/NCT05977673
  7. https://clinicaltrials.gov/study/NCT06692270
  8. https://clinicaltrials.gov/study/NCT05231850